<SEC-DOCUMENT>0001193125-22-181696.txt : 20220627
<SEC-HEADER>0001193125-22-181696.hdr.sgml : 20220627
<ACCEPTANCE-DATETIME>20220624174832
ACCESSION NUMBER:		0001193125-22-181696
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220624
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220627
DATE AS OF CHANGE:		20220624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		221041153

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d387575d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cbio="http://www.catalystbiosciences.com/20220624" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-06-24_to_2022-06-24">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-06-24_to_2022-06-24">0001124105</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cbio-20220624.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-06-24_to_2022-06-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-24</xbrli:startDate> <xbrli:endDate>2022-06-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-06-24_to_2022-06-24">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt:datemonthdayyearen">June&#160;24, 2022</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-06-24_to_2022-06-24">CATALYST BIOSCIENCES, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-06-24_to_2022-06-24">000-51173</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-06-24_to_2022-06-24">56-2020050</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-06-24_to_2022-06-24">611 Gateway Blvd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-06-24_to_2022-06-24">Suite 710</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-06-24_to_2022-06-24">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-06-24_to_2022-06-24">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-06-24_to_2022-06-24">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-06-24_to_2022-06-24">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-06-24_to_2022-06-24">871-0761</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-06-24_to_2022-06-24">Common Stock</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-06-24_to_2022-06-24">CBIO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric></span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-06-24_to_2022-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Catalyst Biosciences, Inc. (&#8220;<span style="text-decoration:underline">Catalyst</span>&#8221;) hereby provides information regarding events leading up to the sale of assets to Vertex Pharmaceuticals Incorporated (&#8220;<span style="text-decoration:underline">Vertex</span>&#8221;) May&#160;19, 2022 (the &#8220;<span style="text-decoration:underline">Transaction</span>&#8221;) as previously disclosed on May&#160;23, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Background of the Transaction </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Transaction and its terms were the result of a competitive process and negotiations between representatives of Catalyst and Vertex. In particular: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;17, 2022, Catalyst announced that it had engaged Perella Weinberg Partners (&#8220;<span style="text-decoration:underline">PWP</span>&#8221;), a leading global independent advisory firm, as a financial advisor to assist Catalyst in exploring strategic alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February&#160;17, 2022, and early April 2022, PWP and Catalyst reviewed Catalyst&#8217;s strategic alternatives, including licensing, sale of assets, and M&amp;A transactions, and engaged with various potential counterparties. This engagement included outreach to approximately 75 potentially interested parties, the execution of confidentiality agreements with 15 parties, due diligence conducted by 14 parties, process letters sent to 13 parties, two offers received by the initial April&#160;7, 2022 deadline for <span style="white-space:nowrap">non-binding</span> indications of interest, including an offer from Vertex, and one subsequent verbal offer received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While PWP and Catalyst were considering Catalyst&#8217;s strategic alternatives, Catalyst announced on March&#160;15, 2022, that it had regained full rights to CB <span style="white-space:nowrap">2782-PEG,</span> a <span style="white-space:nowrap">C3-degrader</span> for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen International GmbH returned the rights for further development of CB <span style="white-space:nowrap">2782-PEG</span> and ended the collaboration on other potential AMD treatments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the process letter sent by PWP to parties that expressed an interest in purchasing the complement assets and other strategic transactions, <span style="white-space:nowrap">non-binding</span> indications of interests were due by April&#160;7, 2022. Catalyst received two preliminary, <span style="white-space:nowrap">non-binding</span> indications of interest, one from Vertex and one from another potential buyer that offered an initial upfront payment plus contingent milestone payments based on product development and regulatory approvals. Catalyst&#8217;s Board of Directors reviewed these proposals with PWP and Catalyst management and discussed negotiating strategies and plans. The Board determined that the offer received from Vertex was superior to the offer received from the other potential buyer based on various factors, including the contingent nature of the other party&#8217;s milestone payments compared to the Vertex bid which offered more cash up front. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2022, a final round process letter was sent to Vertex, requesting a final proposal and markup of the Asset Purchase Agreement by April&#160;28, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;13, 2022, PWP sent Catalyst&#8217;s initial draft of the Asset Purchase Agreement (the &#8220;<span style="text-decoration:underline">Draft APA</span>&#8221;) to Vertex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;13, 2022, Catalyst engaged the law firm Potter Anderson&#160;&amp; Corroon LLP to advise on Delaware law matters with respect to the potential sale of the complement assets, including whether such transaction would require approval of the company&#8217;s stockholders under Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;25, 2022, Catalyst received a preliminary, <span style="white-space:nowrap">non-binding</span> indication of interest from a third potential buyer of the complement assets, on terms that the Board of Directors determined were inferior to Vertex&#8217;s proposal. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&#160;12, 2022 and April&#160;28, 2022, Vertex continued its diligence on Catalyst&#8217;s complement assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2022, Vertex provided a final indication of interest for the acquisition of 100% of the complement assets along with comments and proposed edits to the Draft APA, proposing a $60&#160;million purchase price, without milestones, consisting of a $55&#160;million upfront cash payment at signing and a $5&#160;million holdback payable upon the completion of certain obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&#160;29, 2022 and May&#160;19, 2022, Catalyst and Vertex negotiated the Draft APA, and Vertex continued and completed its diligence of the complement assets. During this period, Potter Anderson&#160;&amp; Corroon engaged with the company and PWP in analysis of the proposed transaction and the value of the assets to be retained by Catalyst following the sale of the complement assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;12, 2022, the Board received the opinion of Potter Anderson&#160;&amp; Corroon LLP that a vote of the Catalyst stockholders to approve the Transaction was not required under Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on May&#160;12, 2022, the Board of Directors of Catalyst discussed the offers received and unanimously resolved to approve the Transaction. Among the factors considered by the Catalyst Board were the consideration offered by Vertex, the amount and duration of the consideration holdback, the superiority of the terms offered by Vertex compared to other offers received following the extensive review of strategic alternatives and sale process, the fact that the Vertex proposal provided for a simultaneous signing and closing of the Transaction which was viewed favorably by the Catalyst Board and the certainty of closing the asset sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;19, 2022, Catalyst and Vertex signed the Asset Purchase Agreement and closed the Transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;23, 2022, Catalyst announced that it had signed the Asset Purchase Agreement with Vertex and closed the Transaction as well as the material terms of the Transaction. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d387575dex991.htm">Asset Purchase Agreement dated as of May&#160;19, 2022 by and between Catalyst Biosciences, Inc. and Vertex Pharmaceuticals Incorporated.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#167;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit (indicated by &#8220;[***]&#8221;) have been redacted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(b)(10)(iv). </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">CATALYST BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;Date: June&#160;24, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nassim Usman</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Nassim Usman, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d387575dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD BE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION HAS BEEN MARKED WITH &#147;[***].&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSET PURCHASE AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">dated
as of May&nbsp;19, 2022, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CATALYST BIOSCIENCES, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VERTEX PHARMACEUTICALS INCORPORATED </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;1. DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Interpretive Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;2. PURCHASE AND SALE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Purchase and Sale</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transferred Assets and Excluded Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assumed Liabilities and Retained Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents to Certain Assignments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;3. CLOSING, PAYMENT, AND DELIVERABLES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of the Closing Consideration; Closing Deliverables</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;4. REPRESENTATIONS AND WARRANTIES OF SELLER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Standing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority, Execution and Delivery; Enforceability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Conflicts or Violations, No Consents or Approvals Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title; No Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Laws; Regulatory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers or Finders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representation or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;5. REPRESENTATIONS AND WARRANTIES OF PURCHASER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Standing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Execution and Delivery, Enforceability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Conflicts or Violations, No Consents or Approvals Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Actions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Availability of Funds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers or Finders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representation or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;6. TAX MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;7. ADDITIONAL AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances to Effectuate the Transaction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Technology Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Compete.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure of and Access to Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;8. GENERAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments; Waivers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment; Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No <FONT STYLE="white-space:nowrap">Third-Party</FONT> Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law; Consent to Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibits </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill of Sale</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment and Assumption Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Assignment Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademark Assignment Agreement</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Index of Defined Terms </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ancillary Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basket</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Code</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidential Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">control</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Damages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enforceability Exceptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excluded Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excluded Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excluded Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exploit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fraud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governmental Entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holdback Amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Know-How</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Knowledge of Seller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Order</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Assignment Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pending Claims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Person</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Platforms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refunds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchaser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchaser Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchaser Indemnified Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seller Governing Documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Set Aside Amounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Straddle Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxing Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Territory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademark Assignment Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred <FONT STYLE="white-space:nowrap">Know-How</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Product Regulatory Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Product Scientific Material</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferred Trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSET PURCHASE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This ASSET PURCHASE AGREEMENT, dated as of May&nbsp;19, 2022 (this&nbsp;&#147;<U>Agreement</U>&#148;), is by and between Catalyst Biosciences,
Inc., a Delaware corporation (&#147;<U>Seller</U>&#148;), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (&#147;<U>Purchaser</U>&#148;). Capitalized terms are defined on the pages of this Agreement set forth opposite such
capitalized terms listed in the Index of Defined Terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Seller desires to sell, transfer, assign, convey, and deliver to
Purchaser, and Purchaser desires to purchase, acquire, and accept from Seller, the Transferred Assets and assume the Assumed Liabilities upon the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Purchaser and Seller desire to make certain representations, warranties, covenants, and agreements in connection with the Transaction
and prescribe various conditions to the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises, the mutual covenants,
promises, and agreements set forth in this Agreement, the mutual benefits to be gained by the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged and accepted, the parties,
intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;1. <U>DEFINITIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Defined Terms</U>. The following terms have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; means any claim, action, suit or proceeding, investigation, governmental inquiry, or criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, when used with respect to a specified Person, another Person that either directly or indirectly, through
one or more intermediaries, controls, is controlled by, or is under common control with, the specified Person. For purposes of this Agreement, &#147;<U>control</U>&#148; means the possession, directly or indirectly, of the power to direct, or cause
the direction of, the management and policies of a Person, whether through ownership of voting securities, contract or otherwise, and &#147;controlled&#148; and &#147;controlling&#148; will have correlative meanings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ancillary Agreements</U>&#148; means (a)&nbsp;a bill of sale providing for the transfer of the Transferred Assets in the form of
<U>Exhibit A</U>, (b)&nbsp;an assignment and assumption agreement for the assumption of the Assumed Liabilities in the form of <U>Exhibit</U><U></U><U>&nbsp;B</U>, (c)&nbsp;the Patent Assignment Agreement, (d)&nbsp;the Trademark Assignment
Agreement, and (e)&nbsp;each document, certificate, or other instrument required to be delivered under this Agreement or under any other Ancillary Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business
Day</U>&#148; means a day, other than a Saturday or a Sunday, on which commercial banks are not required or authorized to close in New&nbsp;York City, New&nbsp;York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Consideration</U>&#148; means the Purchase Price <U>minus</U><I> </I>the Holdback Amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the U.S. Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consulting Agreement</U>&#148; means each of the consulting agreements in a form to be agreed by Purchaser and each individual set
forth on <U>Section</U><U></U><U>&nbsp;7.1(c)</U> of the Disclosure Schedule following the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any
contract, agreement, indenture, note, bond, loan, instrument, lease, conditional sales contract, mortgage, license, or other commitment or arrangement, whether oral or written, that is binding on any Person or any of its property under applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Damages</U>&#148; means the amount of any loss, claim, tax, demand, damage, deficiency, liability, judgment, royalty, fine,
penalty, cost, or expense (including costs of investigation and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket,</FONT></FONT> reasonable attorneys&#146;, consultants&#146; and experts&#146; fees and expenses and
interest and penalties awarded or imposed by a Governmental Entity) incurred, paid, accrued, or sustained by the applicable Purchaser Indemnified Parties; <U>provided</U>, <U>however</U>, that Damages will not include (a)&nbsp;any punitive damages
unless such damages are awarded to a third party, or (b)&nbsp;incidental, special, exemplary, or consequential damages, lost profits, or diminution in value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Schedule</U>&#148; means the disclosure letter in respect of this Agreement delivered by one party to the other party
concurrently with the execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Taxes</U>&#148; means any Taxes (a)&nbsp;imposed by any
applicable Law on Seller for any Tax period, other than Property Taxes that are not attributable to a <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period (as determined pursuant to <U>Section</U><U></U><U>&nbsp;6.1(a)</U>),
(b)&nbsp;imposed on or with respect to the ownership or operation of the Excluded Assets or Retained Liabilities for any Tax period, (c)&nbsp;imposed on or with respect to the acquisition, ownership, or operation of the Transferred Assets for any <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period, (d)&nbsp;that are Property Taxes that are attributable to a <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period (as determined pursuant to
<U>Section</U><U></U><U>&nbsp;6.1(a)</U>), (e) for which the Purchaser or any of its Affiliates is liable (i)&nbsp;as a transferee or successor to Seller or its Affiliates or (ii)&nbsp;pursuant to any contract entered into by Seller or its
Affiliates prior to the Closing, other than Taxes of another Person owed pursuant to a contract that constitutes a Transferred Asset or Assumed Liability or that is entered into in the ordinary course of business, the purpose of which is not
primarily related to Taxes, and (f)&nbsp;that are Transfer Taxes, in each case other than any Taxes for which Purchaser is liable under the terms of this Agreement including <U>Section</U><U></U><U>&nbsp;6.1(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exploit</U>&#148; means to research, develop, design, test, manufacture, have made, use, sell, offer for sale, import, export,
promote, market, distribute, or otherwise commercialize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United&nbsp;States Food and Drug
Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means, with respect to any Person, intentional (and not constructive) misrepresentation in
making of the representations and warranties in <U>Article 4</U> or <U>Article 5</U> (as applicable) with the actual knowledge (as opposed to imputed or constructive knowledge or knowledge that could have been obtained after inquiry, or recklessness
or negligence) of such Person that such representation was false when made and upon which the Person to whom such representation was made (the &#147;<U>Recipient</U>&#148;) has reasonably relied to its detriment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United&nbsp;States generally accepted accounting principles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; means any government, any governmental entity,
commission, board, agency, or instrumentality, and any court, tribunal, or judicial body, whether federal, state, county, local, or foreign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holdback Amount</U>&#148; means $5,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; means any and all (a)&nbsp;Patents, (b)&nbsp;copyrights, copyright registrations, and
applications therefor and all other rights corresponding thereto, rights in data and databases, moral and economic rights of authors and inventors, however denominated and any similar or equivalent rights to any of the foregoing, (c)&nbsp;trade
names, logos, trade dress, trademarks and service marks, trademark and service mark registrations, trademark and service mark applications, and any and all goodwill associated with and symbolized by the foregoing items, (d)&nbsp;rights associated
with trade secrets, confidential and proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including inventions, proprietary processes, formulae, models, and methodologies), industrial designs, and any registrations and
applications therefor, (e)&nbsp;rights of privacy and publicity, (f)&nbsp;social media identifiers and account information and Internet domain names, and (g)&nbsp;other proprietary rights arising under Law, Contract, or otherwise and any other
intellectual property rights or proprietary rights recognized by the Law of each applicable jurisdiction, in each case whether registered or unregistered and including all applications for, and renewals, extensions or reversions of, such rights, and
all similar or equivalent rights or forms of protection in any part of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Inventory</U>&#148; means all inventory or
tangible personal property of Seller used, held for use or otherwise consumed in the research, development, or manufacturing of the Products that, as of the Closing, are in the possession or control of Seller, including all raw materials, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-process,</FONT></FONT> inventories, compounds, cell lines, assays, reagents, ingredients, and samples, in each case to the extent owned or controlled by Seller or its Affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Know</U><U><FONT STYLE="white-space:nowrap">-How</FONT></U>&#148; means all existing and available technical information, <FONT
STYLE="white-space:nowrap">know-how,</FONT> and data including inventions (whether patentable or not), discoveries, trade secrets, specifications, information, instructions, processes, formulae, materials, and other technology, in each case as are
used, held for use or otherwise relate to the Products or the Platforms or to their Exploitation, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical,
and clinical data relating to the Products or the Platforms in the Territory, and that is in existence and owned or controlled by, Seller and/or its Affiliates on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Knowledge of Seller</U>&#148; means the actual knowledge, after due inquiry, of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any and all federal, state, provincial, regional, territorial, and local (a)&nbsp;laws, statutes, statutory
instruments, ordinances, regulations of or by any Governmental Entity, (b)&nbsp;rules, executive orders, consent orders, supervisory requirements, directives, circulars, opinions, interpretive letters, and other office releases, guidelines, and
policies, in each case, with the force of Law, of or by any Governmental Entity, and (c)&nbsp;Orders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liabilities</U>&#148; means all debts, losses, damages, adverse claims,
obligations, liabilities, or commitments of any nature or kind, in each case whether (a)&nbsp;known or unknown, express or implied, primary or secondary, direct or indirect, liquidated or unliquidated, absolute or contingent, accrued or unaccrued,
due or to become due, matured or unmatured, fixed, disputed, liquidated, executory, determined or determinable, (b)&nbsp;in contract, tort, strict liability, or otherwise (including all costs and expenses related to such Liabilities), or
(c)&nbsp;required to be recorded or reflected on a balance sheet prepared in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means any
security interest, pledge, mortgage, lien, charge, adverse claim of ownership or use, restriction on transfer (such as a right of first refusal or other similar rights), defect of title, or other similar encumbrance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, judgment, injunction, or decree issued, promulgated, or entered by or with any Governmental Entity
of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patent Assignment Agreement</U>&#148; means the Patent assignment agreement in the form of
<U>Exhibit</U><U></U><U>&nbsp;C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; means the rights and interests in and to issued patents and pending
patent applications in any country, jurisdiction or region (including inventor&#146;s certificates and utility models), including all provisionals, <FONT STYLE="white-space:nowrap">non-provisionals,</FONT> substitutions, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, and
patents of addition thereof, including patent term extensions and supplementary protection certificates, international patent applications filed under the Patent Cooperation Treaty (PCT) and any foreign equivalents to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permit</U>&#148; means any license, franchise, or permit with any Governmental Entity required by Law for the development,
manufacturing, marketing, commercialization, distribution, or sale of the Products, and/or the ownership or use of the Transferred Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;mechanics&#146;, carriers&#146;, workmen&#146;s, repairmen&#146;s or other similar Liens
arising or incurred in the ordinary course of business, and (b)&nbsp;Liens for Taxes and other governmental charges that are not due and payable, or that are being contested in good faith through appropriate proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual, firm, corporation, partnership, limited liability company, trust, joint venture, Governmental
Entity, or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Platforms</U>&#148; means those degrader platforms identified as of the Closing Date as ProTUNE<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> C3b/C4b degrader, ImmunoTune<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> C3a/C5a, and the protease molecular evolution platform, as further described in the Patents set forth on
<U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax
Period</U>&#148; means any taxable period (or portion thereof) ending on or before the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Products</U>&#148; mean
(a)&nbsp;CB 4332, [***], <FONT STYLE="white-space:nowrap">(b)&nbsp;CB&nbsp;2782-PEG,</FONT> a C3 degrader product, (c)&nbsp;[***], [***], and (d)&nbsp;[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Property Taxes</U>&#148; means real, personal, ad valorem, and intangible property
Taxes and any similar Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Price</U>&#148; means an amount in cash equal to $60,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser Group</U>&#148; means Purchaser and Purchaser&#146;s Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Business</U>&#148; means the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Seller Governing Documents</U>&#148; means Seller&#146;s Certificate of Incorporation and Bylaws, in each case as amended to date in
effect as of the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Straddle Period</U>&#148; means any taxable period beginning on or prior to and ending after the
Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means with respect to any entity, that such entity will be deemed to be a
&#147;Subsidiary&#148; of another Person if such other Person directly or indirectly owns, beneficially or of record, (a)&nbsp;an amount of voting securities of other interests in such entity that is sufficient to enable such Person to elect at
least a majority of the members of such entity&#146;s board of directors or other governing body, or (b)&nbsp;at least a majority of the outstanding equity interests of such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any return, declaration, statement, disclosure, report, form, estimate, or information return relating to
Taxes including any amendments thereto and any related or supporting information, schedules, or attachments thereto, in each case required or permitted to be filed with any Taxing Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means any and all U.S. federal, state, and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes,
assessments, and other similar governmental charges, duties, impositions, levies, customs, tariffs, including taxes based upon or measured by gross receipts, income, profits, gain, sales, use, and occupation, and value added, ad valorem, transfer,
franchise, withholding, payroll, recapture, employment, alternative minimum, estimated, stamp, excise, and Property Taxes, as well as social security, together with all interest, penalties, and additions imposed with respect to such amounts or such
interest, penalties, or additions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxing Authority</U>&#148; means any federal, state, local, or foreign government, any
subdivision, agency, commission, or authority thereof, or any <FONT STYLE="white-space:nowrap">quasi-governmental</FONT> body exercising Tax regulatory authority or otherwise responsible for the imposition, collection, or administration of any Tax.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Territory</U>&#148; means worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademark Assignment Agreement</U>&#148; means the trademark assignment agreement in the form of <U>Exhibit</U><U></U><U>&nbsp;D</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction</U>&#148; means (a)&nbsp;the purchase and sale of the Transferred Assets and the assumption of the Assumed
Liabilities, and (b)&nbsp;all other transactions, in each case as contemplated by this Agreement and the Ancillary Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Taxes</U>&#148; means all sales (including bulk sales and value added
tax), use, transfer, recording, privilege, documentary, registration, conveyance, excise, license, stamp, or similar Taxes and fees arising out of, in connection with, or attributable to the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Contracts</U>&#148; means the Contracts set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Intellectual Property</U>&#148; means (a)&nbsp;the Transferred Patents, (b)&nbsp;the Transferred Trademarks, and
(c)&nbsp;the Transferred <FONT STYLE="white-space:nowrap">Know-How,</FONT> and (d)&nbsp;all other Intellectual Property Rights owned by Seller or any of its Affiliates used, held for use or otherwise related to the Products or the Platforms or their
Exploitation, in each case of (a)&nbsp;through (d) together with all rights and remedies against past, present, and future infringement, misappropriation, or other violation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Inventory</U>&#148; means the Inventory set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule and
all other Inventory used in connection with the research, development, or manufacturing of the Products. For the avoidance of doubt, Transferred Inventory expressly excludes the Excluded Inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred <FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; means the <FONT STYLE="white-space:nowrap">Know-How</FONT> set
forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule and all other <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Patents</U>&#148; means the Patents set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule and all
other Patents related to the Products or the Platforms, together with any and all foreign counterparts thereof, and all related continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT>
divisionals, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> substitutions, and extensions of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Product Regulatory Materials</U>&#148; means the materials set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the
Disclosure Schedule and all other (a)&nbsp;correspondence and reports necessary to, or otherwise describing the ability to, research, develop, manufacture, commercialize or otherwise Exploit the Products in the Territory, submitted to, or received
from any Governmental Entity, including lab notebooks and the like, and (b)&nbsp;all regulatory filings, correspondence, and reports, plans and protocols, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> data and any other data, databases, materials, and information filed with or received from any Governmental Entity used, held for use or otherwise relating to the Products or the Platforms as of
the Closing Date, in each case to the extent owned by, controlled by or in the possession of Seller or its Affiliates, including all correspondence reported to, or received from, the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Product Scientific Material</U>&#148; means the materials set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the
Disclosure Schedule and all other technological, scientific, chemical, biological, pharmacological, toxicological, regulatory, and clinical trial material if and to the extent not filed with a Governmental Entity used, held for use or otherwise
related to the Products or the Platforms that Seller or any of its Affiliates owns in connection with the research, development, and manufacturing of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Trademarks</U>&#148; means the trademarks set forth on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Disclosure Schedule
and all other trademarks used, held for use, or otherwise related to the Products or the Platforms, together with any and all foreign counterparts thereof, and any and all goodwill associated with and symbolized by the foregoing items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Additional Interpretive Matters</U>. Unless otherwise expressly provided
in this Agreement, for purposes of this Agreement, the following rules of interpretation will apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Calculation of Time
Period</U>. When calculating the period of time before which, within which, or following which any act is to be done or step taken under this Agreement, the date that is the reference date in calculating such period will be excluded. If the last day
of such period is a <FONT STYLE="white-space:nowrap">non-Business</FONT> Day, the period in question will end on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Currency and Accounting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Any reference in this Agreement to Dollars, $, or amounts in cash or Liabilities, means, or will be expressed in, United States dollars.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Unless otherwise defined in this Agreement, accounting terms will have the respective meanings assigned to them in accordance with
GAAP consistently applied with the methodologies, practices, classifications, judgments, estimation techniques, assumptions, and principles used by Seller in preparing its audited financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Gender and Number</U>. Any reference in this Agreement to gender will include all genders, and words imparting the singular number only
will include the plural and vice versa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Headings</U>. The provision of a Table of Contents, the division of this Agreement into
Articles, Sections and other subdivisions, and the insertion of headings are for convenience of reference only and will not affect or be utilized in construing or interpreting this Agreement. All references in this Agreement to any
&#147;Section&#148; are to the corresponding Section of this Agreement unless otherwise specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Including</U>. The word
&#147;including&#148; or any variation thereof means &#147;including, without limitation&#148; and will not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Laws and Governmental Entities</U>. Any reference to any Law will be deemed also to refer to all rules and regulations promulgated
thereunder, unless the context requires otherwise. Any reference in this Agreement to (i)&nbsp;a specific rule, regulation, or section or subsection of any Law will be deemed to refer to any amendment or successor provision to such rule, regulation,
or section or subsection of such Law, and (ii)&nbsp;any Governmental Entity, will be deemed to refer to any successor to such Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The parties have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of
intent or interpretation arises, this Agreement will be construed as jointly drafted by the parties and no presumption or burden of proof will arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;2. <U>PURCHASE AND SALE</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Purchase and Sale</U>. Upon the terms and subject to the conditions of this Agreement, at the Closing, Seller will sell,
transfer, assign, convey, and deliver to Purchaser, and Purchaser will purchase, acquire, and accept from Seller, the Transferred Assets in consideration for (a)&nbsp;the payment by Purchaser to Seller of an aggregate amount in cash equal to the
Purchase Price, and (b)&nbsp;the assumption by Purchaser from Seller of the Assumed Liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Transferred Assets
and Excluded Assets</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferred Assets</U>. &#147;<U>Transferred Assets</U>&#148; means all of the assets, properties,
privileges, claims, title, interests, and rights of Seller identified below as such assets exist as of the Closing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Products;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Platforms; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Transferred Intellectual Property; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) the Transferred Product Regulatory Materials; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) the Transferred Product Scientific Materials; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) the Transferred Contracts; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) the Transferred Inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Excluded Assets</U>. Seller will not sell, transfer, assign, convey, or deliver to Purchaser, and Purchaser will not purchase, acquire,
or accept from Seller, any Excluded Assets. &#147;<U>Excluded Assets</U>&#148; means any asset, property, privilege, claim, title, interest, or right of Seller that is not included in Transferred Assets, comprised of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any cash or cash equivalents of Seller; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any accounts receivable of Seller; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any inventory of Seller other than the Transferred Inventory (the&nbsp;&#147;<U>Excluded Inventory</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any and all Tax assets (including refunds and prepayments) (A)&nbsp;of Seller or any Affiliate for any and all Tax periods, and
(B)&nbsp;with respect to Property Taxes imposed&nbsp;with respect to the Transferred Assets or Assumed Liabilities for any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any records (including accounting records and workpapers) related to Taxes paid or payable by Seller or any Affiliate and any financial
and Tax records relating to the Transferred Assets or Assumed Liabilities that form part of the general ledger of Seller or any Affiliate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) all Liabilities in respect of any Action arising out of, relating to, or otherwise in
respect of the Products or the Transferred Assets to the extent such Action relates to operation on or prior to the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)
all Contracts between Seller and any Person, other than the Transferred Contracts; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) all rights of Seller under this Agreement or
any Ancillary Agreement and any related claims; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any other assets as set forth on <U>Section</U><U></U><U>&nbsp;2.2</U> of the
of the Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Assumed Liabilities and Retained Liabilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Assumed Liabilities</U>. &#147;<U>Assumed Liabilities</U>&#148; means only the Liabilities from and after the Closing Date that are
expressly set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) all Liabilities arising out of, relating to, resulting from, or in connection with the Products and the
Transferred Assets arising on or after the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) all Liabilities arising out of, relating to, resulting from, or in
connection with the performance by Purchaser Group under any Transferred Contract from and after the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) all Liabilities
arising out of, relating to, resulting from, or in connection with any Product developed, manufactured, marketed, commercialized, distributed, or sold by Purchaser Group from and after the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) all Liabilities for Taxes (A)&nbsp;relating to the Transferred Assets or the Assumed Liabilities that are attributable to any taxable
period (or portion thereof) beginning after the Closing Date, and (B)&nbsp;for which Purchaser is liable under the terms of this Agreement (including <U>Section</U><U></U><U>&nbsp;6.1(c)</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the purchase and sale of the Transferred Assets under this Agreement, at the Closing, Purchaser will assume and become
responsible for the Assumed Liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Retained Liabilities</U>. Purchaser will not assume or become responsible for any
Retained Liabilities, and Seller will pay, perform, and discharge all Retained Liabilities when due. &#147;<U>Retained Liabilities</U>&#148; means all Liabilities of Seller (including Excluded Taxes and other Liabilities relating to the breach of
this Agreement) other than the Assumed Liabilities that are expressly assumed by Purchaser under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Consents to Certain Assignments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything in this Agreement to the contrary, this Agreement will not constitute an agreement to assign any Transferred
Asset or any claim or right arising under a Transferred Asset or resulting therefrom if such an attempted assignment, without the consent of a third party, would constitute a breach or other contravention thereof or in any way adversely affect the
rights of Seller or Purchaser under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Seller will use its commercially reasonable efforts from and after the date of
this Agreement to obtain the consent of any such third party for the assignment to Purchaser of any such Transferred Asset, including the consents set forth on <U>Section</U><U></U><U>&nbsp;2.4</U> of the Disclosure Schedule. If such consent has not
been obtained prior to the consummation of the Closing, or if an attempted assignment would, in Seller&#146;s reasonable discretion, be ineffective or would adversely affect the rights of Seller thereunder so that Purchaser would not in fact receive
all such rights, Seller will use commercially reasonable efforts to provide Purchaser the benefits thereunder and Purchaser will assume the obligations thereunder (but only to the extent such obligations relate to the benefits that Seller actually
provides to Purchaser and that would have constituted Assumed Liabilities if such assignment occurred on the Closing Date) from and after the consummation of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Seller is not obligated to seek consents prior to the consummation of the Closing. If and when any such consents will be obtained after
the consummation of the Closing, Seller will promptly assign its rights thereunder to Purchaser without payment of consideration and Purchaser will, without payment of any additional consideration, assume from and after the date of such assignment
the obligations thereunder (but only the obligations of Seller thereunder arising exclusively from, and accruing exclusively with respect to, the period after the date of such assignment (other than obligations thereunder arising as a result of the
breach thereof at or prior to such assignment)). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;3. <U>CLOSING, PAYMENT, AND DELIVERABLES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <U>Closing</U>. The closing of the Transaction (the&nbsp;&#147;<U>Closing</U>&#148;) will take place on the date of this
Agreement, which is referred to in this Agreement as the &#147;<U>Closing Date</U>,&#148; by electronic delivery of documents (by &#147;portable document format&#148;, email, or other form of electronic communication) all of which will be deemed to
be originals. The Closing will be deemed to have occurred at 12:01 a.m. Eastern Time on the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2
<U>Payment of the Closing Consideration; Closing Deliverables</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment of the Closing Consideration</U>. At the Closing,
Purchaser will pay to Seller the Closing Consideration by wire transfer of immediately available funds to the account designated on <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Purchaser Deliverables</U>. At the Closing, Purchaser will deliver to Seller each Ancillary Agreement, duly executed by Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Seller Deliverables</U>. At the Closing, Seller will deliver to Purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) an executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> of Seller; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) each Ancillary Agreement, duly executed by Seller. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Withholding</U>. Subject to Seller&#146;s delivery of an executed IRS
Form <FONT STYLE="white-space:nowrap">W-9</FONT> pursuant to <U>Section</U><U></U><U>&nbsp;3.2(c)(i)</U>, Purchaser will not and will cause each of its Affiliates and agents not to deduct or withhold from the payment of any amounts (or any portion
thereof) payable under this Agreement under the Code or any other Tax Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;4. <U>REPRESENTATIONS AND WARRANTIES OF SELLER</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the Disclosure Schedule, Seller represents and warrants to Purchaser as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Organization and Standing</U>. Seller (a)&nbsp;is a corporation duly organized, validly existing, and in good standing
under the Laws of the state of its formation and existence, (b)&nbsp;has all requisite power and authority to carry on its business in all material respects, and (c)&nbsp;is duly qualified to do business and is in good standing in each of the
jurisdictions in which the ownership, operation, or leasing of its properties and assets and the conduct of its business requires it to be so qualified, licensed, or authorized, except for those jurisdictions where the failure to be so qualified,
licensed, or authorized would not reasonably be expected to be material to Seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Authority, Execution and Delivery;
Enforceability</U>. Seller has all necessary corporate power and authority to enter into this Agreement and the other Ancillary Agreements to which it is a party, to perform its obligations under this Agreement and under the Ancillary Agreements,
and to consummate the Transaction. This Agreement and each of the other Ancillary Agreements to which Seller is a party has been duly executed and delivered by Seller, and (assuming due authorization, execution, and delivery by the other parties and
such other Ancillary Agreements) constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium, and other
similar laws relating to or affecting creditors&#146; rights generally or by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law) (the&nbsp;&#147;<U>Enforceability
Exceptions</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>No Conflicts or Violations, No Consents or Approvals Required</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement and the Ancillary Agreements by Seller, the performance by Seller of its obligations under
this Agreement and under the Ancillary Agreements, and the consummation by Seller of the Transaction, does not and will not, directly or indirectly, (i)&nbsp;conflict with, or result in any violation of the Seller Governing Documents,
(ii)&nbsp;conflict with or result in a violation of any Permit, Order, or Law applicable to Seller or the Transferred Assets, (iii)&nbsp;violate, conflict with, result in a breach of, or constitute a default (or event which with the giving of notice
or lapse of time, or both, would become a default) under, any Transferred Contract, or (iv)&nbsp;result in the creation of any Lien (not including Permitted Liens) upon any of the Transferred Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No consent of, or registration, declaration, notice, or filing with, any Governmental Entity is required to be obtained, made, or given by
Seller in connection with the execution, delivery, and performance of this Agreement and the other Ancillary Agreements to which Seller is a party, or the consummation of the Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <U>Title; No Activities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Seller has good, valid, and marketable title to each of the Transferred Assets, in each case, free and clear of all Liens (other than
Permitted Liens), and is in possession of or has control over such Transferred Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Seller and its Affiliates have not marketed,
commercialized, distributed, or sold any of the Products at any time prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Transferred Inventory is of a
quality and quantity usable in the ordinary course of business consistent with past practice, except in each case for excess, damaged, obsolete, or expired items (which, for the avoidance of doubt, are deemed Excluded Assets). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Transferred Assets constitute all of the assets of Seller used or created by Seller as of the Closing Date in the Exploitation of any
Product or Platform or that are controlled by Seller and would reasonably be expected to be used by Seller in the Exploitation of any Product or Platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5
<U>Contracts</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Transferred Contract constitutes a valid and binding obligation of Seller, enforceable against Seller in
accordance with its terms, except as enforceability may be limited by the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Seller has performed all
obligations, in all material respects, required to be performed by it under each Transferred Contract, and Seller is not in material breach or default thereunder and, to the Knowledge of Seller, no other party to such Transferred Contract is in
material breach or default thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No counterparty to any Transferred Contract has notified Seller in writing that such
counterparty (i)&nbsp;intends to cease, after the Closing Date, providing its goods or services under such Transferred Contract, or (ii)&nbsp;intends to terminate or materially reduce, after the Closing Date, its relationship with Seller under such
Transferred Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <U>Compliance</U><U> with Laws; Regulatory</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Seller&#146;s Exploitation of the Platform and the Products is, in all material respects, in compliance with all applicable Law and
Orders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Seller has not received any written notice from any Governmental Entity alleging any failure of the Exploitation of the
Platform and the Products to comply with any applicable Law or Order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section 4.6(c)</U> of the Disclosure Schedule lists all Permits currently held by
Seller in connection with the Exploitation of the Products by Seller. Seller is not in violation or default in any material respect of any such Permit. Seller has not received any notice or other communication (whether written or oral) from any
Governmental Entity that it intends to or is threatening to revoke, suspend, modify, or limit any such Permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any Transferred
Product Regulatory Materials were, at the time of filing, true and complete in all material respects. Since the date Seller first owned any of the Products, none of Seller, any Affiliate, or any of their officers, employees, or agents has
(i)&nbsp;made an untrue statement of a material fact to any Governmental Entity with respect to any Product, (ii)&nbsp;failed to disclose a material fact required to be disclosed to a Governmental Entity with respect to any Product, or
(iii)&nbsp;committed an act with respect to any Product that would reasonably be expected to provide a basis for the FDA to invoke its policy in respect of &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; set
forth in 56&nbsp;Fed.&nbsp;Reg.&nbsp;46191 (September 10, 1991), as amended. Seller has made available to Purchaser true and complete copies of all material correspondence with any Governmental Entity in Seller&#146;s possession or control with
respect to the Transferred Product Regulatory Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither Seller nor any person employed by Seller (i)&nbsp;is, to the
Knowledge of Seller, under investigation by the FDA for debarment action or is presently or has been debarred pursuant to Section&nbsp;306(a) or (b)&nbsp;of the U.S. Generic Drug Enforcement Act of&nbsp;1992, or (ii)&nbsp;has a disqualification
hearing pending or has been disqualified by the FDA under 21&nbsp;C.F.R.&nbsp;Section 312.70. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no (i)&nbsp;outstanding Order
against Seller, (ii)&nbsp;Action pending or, to the Knowledge of Seller, threatened against Seller, or (iii)&nbsp;to the Knowledge of Seller, any investigation by any Governmental Entity pending or threatened against Seller, in the case of each of
clauses&nbsp;(i), (ii), and (iii), in respect of the Products or any of the Transferred Assets including any Action to place a clinical hold order on, or otherwise terminate, delay, or suspend, any proposed or ongoing
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical studies, trials, investigational new drug applications, or investigations conducted or proposed to be conducted in connection with the Transferred Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <U>Intellectual</U><U> Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Seller is the sole and exclusive legal and beneficial and, with respect to the Transferred Patents and the Transferred Trademarks, record
owner of all right, title, and interest in and to the Transferred Intellectual Property. Each issued Transferred Patent and each issued Transferred Trademark is subsisting in full force and effect, and to the Knowledge of Seller, valid and
enforceable. Seller has taken all reasonable and necessary steps to maintain and enforce the Transferred Patents and the Transferred Trademarks. All required filings and fees related to the Transferred Patents and the Transferred Trademarks have
been timely submitted with and paid to the relevant Governmental Entities and authorized registrars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Seller takes reasonable measures
to protect the confidentiality of the Transferred <FONT STYLE="white-space:nowrap">Know-How,</FONT> including requiring all Persons having access thereto to execute written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements. There has
not been any unauthorized disclosure of or access to any such Transferred <FONT STYLE="white-space:nowrap">Know-How</FONT> in a manner that has resulted or is likely to result in the loss of trade secret or other rights in and to such information or
the further dissemination or disclosure of such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Seller nor any of its Affiliates owns or has any right, title, or interest in or
to any Intellectual Property Rights related to the Products or the Platforms other than Transferred Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither the execution,
delivery, or performance of this Agreement, nor the consummation of the Transactions, will result in the loss or impairment of or payment of any additional amounts with respect to, or require the consent of any other Person in respect of,
Purchaser&#146;s right to own or use the Transferred Intellectual Property. Immediately following the Closing Date, all the Transferred Intellectual Property will be owned by Purchaser on identical terms as they were owned or available for use by
Seller immediately prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No funding, facilities, or personnel of any Governmental Entity, educational or
research institution were used, directly or indirectly, to develop or create, in whole or in part, any Transferred Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the Knowledge of Seller, (i)&nbsp;no Person has infringed, misappropriated, or otherwise violated any of the Transferred Intellectual
Property, and (ii)&nbsp;the Exploitation of the Products and Platforms as are currently and have been Exploited and as are currently contemplated to be Exploited do not infringe, misappropriate, or otherwise violate any valid Intellectual Property
Rights of any other Person. There are, and have been, no claims brought or asserted (including in the form of an offer to obtain a license) (i)&nbsp;alleging that the Exploitation of the Products and Platforms infringes, violates, or misappropriates
any Intellectual Property Rights of any other Person, (ii)&nbsp;challenging the validity, enforceability, registrability, patentability, or ownership of any Transferred Intellectual Property, or Seller&#146;s (or its Affiliates&#146;) rights with
respect to any Transferred Intellectual Property, or (iii)&nbsp;by Seller (or its Affiliates) alleging any infringement, misappropriation, or other violation by any Person of any Transferred Intellectual Property. Neither Seller nor any of its
Affiliates are subject to any outstanding or prospective Order that does or could reasonably be expected to restrict or impair the ownership or use by Purchaser of any Transferred Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <U>Taxes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All material Tax Returns related to the Transferred Assets or Assumed Liabilities that are or were required to be filed on or prior to the
Closing Date have been timely filed. All such Tax Returns are true and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes related
to the Transferred Assets or Assumed Liabilities that are due or have become due on or prior to the Closing Date have been paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There are no Liens other than Permitted Liens on any of the Transferred Assets related to any material Taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Action, audit or other proceeding regarding any material Tax or material Tax Return
related to the Transferred Assets or Assumed Liabilities is pending, and no written notice of any material Tax deficiency outstanding, or assessed has been received, or, in each case, to the Knowledge of Seller, proposed or threatened in writing by
any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no outstanding extensions or waivers of the statutory period of limitation applicable to any claim
for, or the period for the collection or assessment of, material Taxes with respect to the Transferred Assets or Assumed Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <U>Brokers or Finders</U>. Except for Perella Weinberg Partners, Seller has not incurred any liability or obligation to any
party for any brokerage, investment bankers&#146; or finders&#146; fees, or commissions in connection with the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <U>No Other Representation or Warranties</U>. Except for the representations and warranties contained in this
<U>Article</U><U></U><U>&nbsp;4</U>, none of Seller or any other Person makes any express or implied representation or warranty on behalf of Seller and its Subsidiaries, and Seller and its Subsidiaries disclaim any such representation or warranty,
whether by Seller or its Subsidiaries, or any of their respective representatives or any other Person, with respect to the execution and delivery of this Agreement, the Transactions, or the Transferred Assets, notwithstanding the delivery or
disclosure to Purchaser or any of their respective representatives or any other Person of any documentation or other information with respect to the foregoing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;5. <U>REPRESENTATIONS AND WARRANTIES OF PURCHASER</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchaser represents and warrants to Seller as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Organization and Standing</U>. Purchaser (a)&nbsp;is duly organized, validly existing, and in good standing under the Laws
of the Commonwealth of Massachusetts, (b)&nbsp;has all requisite corporate power and authority to carry on its business as it is now being conducted in all material respects, and (c)&nbsp;is duly qualified to do business and is in good standing in
each of the jurisdictions in which the ownership, operation, or leasing of its properties and assets and the conduct of its business requires it to be so qualified, licensed, or authorized, except for those jurisdictions where the failure to be so
qualified, licensed, or authorized would not have a material adverse effect on Purchaser or materially impair the ability of Purchaser to consummate the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Authority; Execution and Delivery, Enforceability</U>. Purchaser has all necessary corporate power and authority to enter
into this Agreement and the other Ancillary Agreements to which it is a party, to perform its obligations under this Agreement and under the Ancillary Agreements, and to consummate the Transaction. This Agreement and the other Ancillary Agreements
to which Purchaser is a party have been duly executed and delivered by Purchaser and (assuming due authorization, execution, and delivery by the other parties) constitute a valid and binding obligation of Purchaser, enforceable against Purchaser in
accordance with their terms, except as enforceability may be limited by the Enforceability Exceptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>No Conflicts or Violations, No Consents or Approvals Required</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement and the other Ancillary Agreements to which Purchaser is a party, the performance by
Purchaser of its obligations under this Agreement and under the Ancillary Agreements, and the consummation by Purchaser of the Transaction, does not and will not, directly or indirectly, (i)&nbsp;conflict with, or result in, any violation of the
Purchaser&#146;s certificate of incorporation and bylaws, (ii)&nbsp;conflict with or result in a violation of any Permit, Order, or Law applicable to Purchaser, or any of its Subsidiaries, property or assets, or (iii)&nbsp;violate, conflict with,
result in a breach of, or constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, or give rise to a right of termination, cancellation, or acceleration of any obligation or to loss of
a benefit under, or result in the creation of any Lien (not including Permitted Lien) upon any of the properties, rights, or assets of Purchaser or any of its Subsidiaries pursuant to, any Contract to which Purchaser or any of its Subsidiaries is a
party or by which Purchaser or any of its Subsidiaries is bound or affected, except in the case of clauses (ii)&nbsp;and (iii), any such conflicts, violations, defaults, rights, or Liens that would not have a material adverse effect on Purchaser or
its Subsidiaries, taken as a whole, or prevent or materially delay or impair the ability of Purchaser to consummate the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
No consent of, or registration, declaration, notice, or filing with, any Governmental Entity or other Person is required to be obtained or made by, or given to, Purchaser or any of its Subsidiaries in connection with the execution, delivery, and
performance of this Agreement or the consummation of the Transaction, except where the failure to obtain such consent or to make such registration, declaration, notice, or filing would not, individually or in the aggregate, reasonably be expected to
have a material adverse effect on Purchaser or its Subsidiaries, taken as a whole, or prevent or materially delay or impair the ability of Purchaser to consummate the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Actions</U>. There are no Actions pending by or against or, to the knowledge of Purchaser, threatened against, Purchaser
or any Subsidiaries or Affiliates of Purchaser, or any executive officer or director of Purchaser in his or her capacity as such that would prevent or materially delay or impair the ability of Purchaser to consummate the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5 <U>Availability of Funds</U>. Purchaser has available cash and capacity under existing borrowing facilities which together
are sufficient to enable it to consummate the Transaction and to pay all amounts contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6
<U>Brokers or Finders</U>. Purchaser has not incurred any liability or obligation to any party for any brokerage, investment bankers&#146; or finders&#146; fees, or commissions in connection with the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7 <U>No Other Representation or Warranties</U>. Except for the representations and warranties contained in this
<U>Article</U><U></U><U>&nbsp;5</U>, none of Purchaser or any other Person makes any express or implied representation or warranty on behalf of Purchaser and its Subsidiaries, and Purchaser and its Subsidiaries disclaim any such representation or
warranty, whether by Purchaser or its Subsidiaries, or any of their respective representatives or any other Person, with respect to the execution and delivery of this Agreement or the Transactions, notwithstanding the delivery or disclosure to
Seller or any of their respective representatives or any other Person of any documentation or other information with respect to the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;6. <U>TAX MATTERS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Allocation of Taxes</U>. In the case of any Straddle Period, (i)&nbsp;income Taxes, sales and use Taxes, and value added Taxes will be
computed as if such taxable period ended on (and included) the Closing Date, and (ii)&nbsp;all other Taxes (including Property Taxes) for the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period will be equal to the amount of such Taxes
for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of days during the Straddle Period that are in the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period (determined as if the Straddle Period
ended on the Closing Date) and the denominator of which is the number of days in the entire Straddle Period. For the avoidance of doubt, each of Seller and Purchaser shall be responsible for its own income, gross receipts, franchise, and similar
Taxes, and any income, gross receipts, franchise, or similar Tax liability of Seller or any of its Affiliates shall constitute a Retained Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Purchase Price Allocation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No later than 90&nbsp;days after the Closing Date, Seller will deliver to Purchaser a statement (the&nbsp;&#147;<U>Allocation
Statement</U>&#148;) allocating the Purchase Price (increased by the Assumed Liabilities and any other items to the extent properly taken into account under Section&nbsp;1060 of the Code) among the Transferred Assets and any other assets to the
extent properly treated as acquired for Tax purposes pursuant to this Agreement in accordance with Section&nbsp;1060 of the Code. If, within 30&nbsp;days after the delivery of the Allocation Statement, Purchaser has not notified Seller in writing
that Purchaser objects to the allocation set forth in the Allocation Statement, the Allocation Statement will become final and binding on the parties. If, within such <FONT STYLE="white-space:nowrap">30-day</FONT> period, Purchaser has so notified
Seller, Purchaser and Seller will use commercially reasonable efforts to resolve such dispute within 30&nbsp;days. In the event that Purchaser and Seller are able to resolve such dispute within such <FONT STYLE="white-space:nowrap">30-day</FONT>
period, the allocation reflected on the Allocation Statement will be adjusted to reflect such resolution and the Allocation Statement (as so adjusted) will become final and binding on the parties. In the event that Purchaser and Seller are unable to
resolve such dispute within such <FONT STYLE="white-space:nowrap">30-day</FONT> period, such dispute will be resolved by a neutral independent accounting firm mutually acceptable to the parties, with the reasonable costs of such accounting firm to
be borne equally by each of Seller and Purchaser.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>The Allocation Statement as determined by such accounting firm will be final and binding on the parties, unless otherwise required by a change in
Law after the date of this Agreement, a closing agreement with an applicable Taxing Authority, or a final judgment of a court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Once the Allocation Statement becomes final and binding pursuant to <U>Section</U><U></U><U>&nbsp;6.1(b)(i)</U>, the parties agree to
(A)&nbsp;be bound by the Allocation Statement for all Tax purposes, and (B)&nbsp;act in accordance with the Allocation Statement in the preparation, filing, and audit of any Tax Return, in each case, unless otherwise required by a change in Law
occurring after the date that the Allocation Statement becomes final and binding, a closing agreement with an applicable Taxing Authority or a final judgment of a court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Transfer Taxes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All Transfer Taxes will be split 50% / 50% by Purchaser and Seller. The parties will use commercially reasonable efforts to obtain any
available exemption from any Transfer Taxes and will cooperate with the other parties in providing any information and documentation that may be necessary to obtain any such exemption, including any applicable resale or exemption certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Purchaser will prepare and file, or caused to be filed, all Tax Returns and other documentation required to be prepared and filed with
respect to all Transfer Taxes and, if required by applicable Law, Seller will join in the execution of any such Tax Returns and other documentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Purchaser and Seller agree to use reasonable efforts to provide each other with such information and assistance as is reasonably
necessary, including access to records which are in such party&#146;s possession, or are reasonably obtainable without undue burden or expense, and personnel, for the preparation of any Tax Return or for the defense of any Tax claim or assessment
related to the Transferred Assets or the Assumed Liabilities, whether in connection with an audit or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Purchaser will
prepare or cause to be prepared and file or cause to be filed all Tax Returns for the Transferred Assets and the Assumed Liabilities with respect to any Tax period ending after the Closing Date. Seller will prepare or cause to be prepared and file
or cause to be filed all Tax Returns with respect to the Transferred Assets and the Assumed Liabilities with respect to any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period. Seller will provide Purchaser a minimum of 30&nbsp;days to
review and comment on any Tax Return with respect to any Straddle Period prior to filing, and Seller will incorporate any comments reasonably made by Purchaser to such Tax Returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The amount of any Tax refunds or credits that are received by Purchaser with respect to any Transferred Assets or the Assumed Liabilities
that are attributable to any <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period (&#147;<U>Pre</U><U><FONT STYLE="white-space:nowrap">-Closing</FONT> Tax Refunds</U>&#148;) will be for the account of Seller, and Purchaser will cause to be
paid over to Seller any such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refunds, and any interest received thereon, within 30 days after the earlier of receipt or entitlement thereto. Purchaser agrees to claim or cause to be claimed or
utilize or cause to be utilized any such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refund and to furnish Seller all information, records, and assistance necessary to verify the amount of the
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refunds. All such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refunds will be claimed in cash rather than as a credit against future Liabilities. Purchaser will, if Seller so
requests, cause the relevant entity (Purchaser, any of its Affiliates or any successors thereof) to file for and obtain any such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Refunds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Following the Closing, except with the prior written consent of Seller (not to be unreasonably withheld, conditioned, or delayed),
Purchaser will not, and will not cause its Affiliates to, take any action with respect to Taxes of the Transferred Assets or the Assumed Liabilities or any Tax Return with respect thereto (including filing an amended Tax Return or entering a
voluntary disclosure agreement) to the extent that such action would materially adversely affect Seller or any of Seller&#146;s Affiliates, including materially increasing Seller&#146;s Taxes or Seller&#146;s obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer
or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Transferred Assets to Purchaser; it being understood that any Liabilities arising out of the failure of Seller to comply with the
requirements and provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction which would not otherwise constitute Assumed Liabilities will be treated as Retained Liabilities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;7. <U>ADDITIONAL AGREEMENTS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <U>Further</U><U> Assurances to Effectuate the Transaction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Each party agrees (i)&nbsp;to furnish upon request to each other party such further information, (ii)&nbsp;to execute and
deliver to each other party such other documents, and (iii)&nbsp;to do such other acts and things, all as another party may reasonably request for the purpose of carrying out the intent of this Agreement and the other Ancillary Agreements and the
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Return of Retained Liabilities; Transfer of Transferred Assets</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If, during the period beginning on the Closing Date and ending on the [***]anniversary of the Closing Date, any member of the Purchaser
Group is found subject to a Retained Liability, (A)&nbsp;such member of the Purchaser Group will return or transfer and convey (without further cost or consideration to the Purchaser Group) to Seller or the appropriate Subsidiary thereof such
Retained Liability, (B)&nbsp;Seller will, or will cause its appropriate Subsidiary to, assume (without further cost or consideration to the Purchaser Group) such Retained Liability, and (C)&nbsp;Seller and the applicable member of the Purchaser
Group will, and will cause their appropriate Subsidiaries to, execute such documents or instruments of conveyance and assumption and take such further acts as are reasonably necessary or desirable to effect the transfer of such Retained Liability
back to Seller or its appropriate Subsidiaries such that each party is put into the same economic position with respect to such Retained Liability as if such action had been taken on or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If, during the period beginning on the Closing Date and ending on the [***]anniversary of the Closing Date, any asset held by Seller or
its Subsidiaries is ultimately determined to be a Transferred Asset, (A)&nbsp;Seller or its Subsidiary will return or transfer and convey (without further cost to or consideration from the Purchaser Group) to the appropriate member of the Purchaser
Group such Transferred Asset, and (B)&nbsp;Seller and the applicable member of the Purchaser Group will, and will cause their appropriate Subsidiaries to, execute such documents or instruments of conveyance and assumption and take such further acts
as are reasonably necessary or desirable to effect the transfer of such Transferred Asset back to the applicable member of the Purchaser Group such that each party is put into the same economic position with respect to such Transferred Asset as if
such action had been taken on or prior to the Closing Date. In furtherance of the foregoing, Seller will promptly pay or deliver to the applicable member of the Purchaser Group (or its designee) any monies or checks which have been sent to Seller or
its Subsidiary to the extent they are not due to Seller or such Subsidiary and should have been sent to the Purchaser Group (including promptly forwarding invoices or similar documentation to the applicable member of the Purchaser Group). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Except to the extent otherwise required by applicable Law, each of Seller and
Purchaser will, and will cause its Subsidiaries to, cooperate to effectuate the transfers contemplated by this Section in a manner that is <FONT STYLE="white-space:nowrap">tax-efficient</FONT> for the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Seller will use its commercially reasonable efforts to, at Purchaser&#146;s sole cost and expense, make available for hiring the list of
individuals identified on <U>Section</U><U></U><U>&nbsp;7.1(c)</U> of the Disclosure Schedule whom Purchaser wishes to engage as consultants following the Closing and, to the extent requested by Purchaser, waive any restrictive covenants applicable
to such individuals. Purchaser may, in its own discretion, provide to each of the individuals listed on <U>Section</U><U></U><U>&nbsp;7.1(c)</U> of the Disclosure Schedule a Consulting Agreement; <U>provided</U>, <U>however</U>, that Purchaser will
be in no way obligated to enter into any consulting agreement with any individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <U>Technology Transfer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Seller and Purchaser will use commercially reasonable efforts to effect an orderly transfer of the Transferred Product Scientific Material
and the Transferred <FONT STYLE="white-space:nowrap">Know-How,</FONT> as applicable, from Seller to Purchaser Group under the terms of this Agreement as promptly as practicable after the Closing to the extent not so transferred at Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In furtherance of <U>Section</U><U></U><U>&nbsp;7.2(a)</U>, without limiting such Section, Seller will take the steps set forth on
<U>Section</U><U></U><U>&nbsp;7.2</U> of the Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In connection with activities undertaken pursuant to this Section,
Seller will bear the costs incurred by Seller and Purchaser will bear the costs incurred by Purchaser Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <U><FONT
STYLE="white-space:nowrap">Non-Compete</FONT></U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of [***]&nbsp;years beginning on the Closing Date, neither Seller nor
any of its controlled Affiliates will, directly or indirectly, engage or participate in, or render services to (whether as an owner, operator, member, shareholder, trustee, manager, consultant, strategic partner, employee or otherwise, with or
without compensation) any Restricted Business. For the purposes of the foregoing, neither Seller nor any of its controlled Affiliates will be in breach of this Section by reason of its beneficial ownership, of two percent or less of the equity of a
Person that engages in any Restricted Business so long as Seller or any of its Affiliates does not control the operation or management of such Person that engages in any Restricted Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties acknowledge and agree that the restrictions contained in this Section are a reasonable and necessary protection of the
immediate interests of Purchaser, and any violation of these restrictions would cause substantial harm to Purchaser and that Purchaser would not have entered into this Agreement and the other Ancillary Agreements without receiving the additional
consideration offered by Seller or its controlled Affiliates in binding themselves to these restrictions. In the event of a breach or a threatened breach by Seller or any of its controlled Affiliates of these restrictions, Purchaser may be entitled
to an injunction restraining Seller or such controlled Affiliate from such breach or threatened breach (without the necessity of proving the inadequacy as a remedy of money damages or the posting of a bond); <U>provided</U>, <U>however</U>, that the
right to injunctive relief will not be construed as prohibiting Purchaser from pursuing any other available remedies, whether at Law or in equity, for such breach or threatened breach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4 <U>Disclosure of and Access to Information</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Public Disclosure</U>. Purchaser and Seller will obtain the prior written consent from each other prior to issuing, and will provide
each other with reasonable advance notice to review and comment upon, any press release or public announcement relating to this Agreement or the Transactions; <U>provided</U>, <U>however</U>, that a party may make such disclosure to the extent
disclosure of the information in such press release or public announcement is required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Confidentiality</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each of Purchaser and Seller acknowledges that the information provided to it in connection with this Agreement and the Transaction
is subject to the terms of the Confidentiality Agreement between Purchaser and Seller, dated November&nbsp;18,&nbsp;2021 (the&nbsp;&#147;<U>Confidentiality Agreement</U>&#148;). The terms of the Confidentiality Agreement are incorporated in this
Agreement by reference. Effective upon, and only upon, the Closing, the Confidentiality Agreement will terminate with respect to information relating solely to the Product and the Transferred Assets (other than information relating to the Excluded
Assets and the personnel of Seller). For the avoidance of doubt, Purchaser acknowledges and agrees that any and all other information provided to it by Seller or any of its representatives concerning Seller or its business will remain subject to the
terms and conditions of the Confidentiality Agreement from and after the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Seller recognizes that it possesses information
of a confidential or secret nature in both written and unwritten form, which is related to the Transferred Assets (hereinafter referred to as &#147;<U>Confidential Information</U>&#148;). For purposes of this Agreement, the foregoing,
&#147;<U>Confidential Information</U>&#148;: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) may include each of the following, to the extent constituting a Transferred Asset:
(I)&nbsp;any <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, pharmaceutical development, prescription, or sales and marketing data for the Products; (II)&nbsp;trade secrets, processes, methods, data,
<FONT STYLE="white-space:nowrap">know-how,</FONT> prototypes, improvements, inventions, techniques, product plans, strategies and forecasts, including any development plans for the use of the Products; (III)&nbsp;forms, Contracts, or promotional
materials created for or used solely in relation to the Products; (IV)&nbsp;any correspondence, memoranda, or files related solely to the Products that contain Confidential Information; and (V)&nbsp;any information, knowledge, and data solely
related to the Transferred Assets; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) will not include (I)&nbsp;any information which is or becomes generally available to and
known by the general public (other than as a result of a disclosure through the actions of Seller or any of its representatives in violation of this Section or any other obligation of confidentiality owed to Purchaser or any of Purchaser&#146;s
Subsidiaries), (II)&nbsp;any information which is or becomes available to Seller on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a third party (other than as a result of a violation of such third party of obligations of
confidentiality), and (III)&nbsp;any information, forms, Contracts, or other items constituting Excluded Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Seller agrees that, following the Closing, all Confidential Information will be the
sole property of Purchaser Group and its assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Seller will, and will cause its representatives to, keep in strict confidence all
Confidential Information and will not use or disclose any Confidential Information or anything relating to it, in whole or in part, or permit others to use or disclose Confidential Information in any way, without the prior written consent of
Purchaser. Seller agrees to inform Purchaser as promptly as practicable in writing in the event of any breach of this obligation of confidentiality that becomes known to Seller. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Notwithstanding anything contained in this Agreement to the contrary, Seller is permitted to disclose the Confidential Information
pursuant to an Order; <U>provided</U> that, in each instance, Seller (A)&nbsp;promptly notifies Purchaser of the Order after Seller becomes aware of the Order, (B)&nbsp;cooperates with Purchaser in seeking a protective order or similar relief to
protect the confidentiality of the information to be disclosed, and (C)&nbsp;limits the disclosure to what is requested by the Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Post-Closing Access to Information</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) For a period of [***] years following the Closing, Purchaser will, and will cause the
other members of Purchaser Group to, afford to Seller and its accountants, counsel, and other representatives reasonable access, upon reasonable prior written notice during normal business hours, to the books and records, Contracts, and other
properties and assets of Purchaser Group solely to the extent relating to the Products, the Transferred Assets, or the Assumed Liabilities solely to the extent in existence prior to the Closing for any reasonable business purpose if such access does
not unreasonably disrupt the normal operations of Purchaser Group. Notwithstanding the immediately foregoing sentence, this Section will not obligate any member of Purchaser Group to (A)&nbsp;adversely affect the ability of any member of Purchaser
Group to assert <FONT STYLE="white-space:nowrap">attorney-client</FONT> or attorney work product privilege or a similar privilege, (B)&nbsp;furnish information, documents, or records if the parties are in an adversarial relationship in litigation or
arbitration, in which case the applicable rules relating to discovery will govern, (C)&nbsp;violate any applicable Law or Order, or (D)&nbsp;breach any duty of confidentiality owed to any Person whether such duty arises contractually, statutorily,
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) For a period of [***] years following the Closing, Seller will afford to Purchaser and its accountants, counsel, and
other representatives reasonable access, upon reasonable prior written notice during normal business hours, to the books and records, Contracts, and other properties and assets of Seller solely to the extent relating to the Products, the Transferred
Assets, or the Assumed Liabilities solely to the extent in existence prior to the Closing for any reasonable business purpose if such access does not unreasonably disrupt the normal operations of Seller. Notwithstanding the immediately foregoing
sentence, this Section will not obligate Seller to (A)&nbsp;adversely affect the ability of Seller to assert attorney-client or attorney work product privilege or a similar privilege, (B)&nbsp;furnish information, documents, or records if the
parties are in an adversarial relationship in litigation or arbitration, in which case the applicable rules relating to discovery will govern, (C)&nbsp;violate any applicable Law or Order, or (D)&nbsp;breach any duty of confidentiality owed to any
Person whether such duty arises contractually, statutorily, or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;8. <U>GENERAL PROVISIONS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>Indemnification</U><U> Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Survival</U>. All representations and warranties of Seller contained in this Agreement or in any document, certificate, or other
instrument required to be delivered under this Agreement or under any other Ancillary Agreements will survive the Closing and will continue until [***] year after the Closing Date (the&nbsp;&#147;<U>Survival Period</U>&#148;). All covenants and
agreements contained in this Agreement or in any other Ancillary Agreement will survive the Closing and will continue until [***] years after the Closing Date. All claims for indemnification relating to the Excluded Assets and the Retained
Liabilities will survive the Closing and continue in effect until 60&nbsp;days after the expiration of the applicable statute of limitations, taking into account any extensions or waivers thereof. Notwithstanding the foregoing, (x)&nbsp;if any
claims for indemnification have been asserted with respect to a misrepresentation, inaccuracy, or a breach of such representations and warranties prior to the end of the Survival Period, such claims will survive and continue in effect until final
resolution of such claims, and (y)&nbsp;claims for indemnification relating to Fraud will survive the Closing and continue in effect until 60&nbsp;days after the expiration of the applicable statute of limitations, taking into account any extensions
or waivers thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Purchaser Indemnity Rights</U>. Subject to the limitations in this <U>Section</U><U></U><U>&nbsp;8.1</U>, from
and after Closing, Seller will pay, defend, discharge, indemnify, and hold harmless Purchaser and the Purchaser Group and each of their Affiliates and each of Purchaser&#146;s, its Subsidiaries&#146;, and its Affiliates&#146; respective officers,
directors, employees, and agents (collectively, the&nbsp;&#147;<U>Purchaser Indemnified Parties</U>&#148;) from and against any Damages arising from or in connection with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the failure of Seller to duly perform or observe any covenant or agreement to be performed or observed by Seller under this Agreement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any breach or inaccuracy of any representation or warranty made by Seller in <U>Article 4</U> of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Excluded Assets or the Retained Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Limitations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
Except in the case of Fraud claims, Seller&#146;s cumulative aggregate indemnification obligation under (A)<U>&nbsp;Section</U><U></U><U>&nbsp;8.1(b)(ii)</U> will not exceed, in the aggregate, the Holdback Amount, and
(B)<U>&nbsp;Section</U><U></U><U>&nbsp;8.1(b)(i)</U> and <U>Section</U><U></U><U>&nbsp;8.1(b)(iii)</U> will not exceed, in the aggregate, the sum of the Closing Consideration <U>plus</U> the amount of the Holdback Amount actually released under
<U>Section</U><U></U><U>&nbsp;8.1(e)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Purchaser acknowledges and agrees that, except as otherwise provided in this
Agreement, Seller will not have any liability under any provision of this Agreement for any Damages to the extent that such Damages are caused by action or inaction by Purchaser or any of its Subsidiaries or Affiliates after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Damages will be limited to the amount of any Damages that remain after deducting therefrom any insurance proceeds and any indemnity,
contribution, or other similar payment actually received by the Purchaser Indemnified Parties from any third parties in respect of any such claim, net of any costs of recovery and increases in premiums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Damages will be determined without duplication of any other Damages for which an indemnification claim has been paid under any other
representation, warranty, covenant, or agreement among the parties. The Purchaser Indemnified Parties will not be entitled to recover more than once for the same Damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) For purposes of determining the amount of Damages resulting from a breach or inaccuracy of a representation or warranty and for purposes
of determining whether there has been any breach or inaccuracy of a representation or warranty, all qualifications or exceptions in any representation or warranty relating to or referring to the term &#147;material&#148; shall be disregarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Seller will not be required to provide indemnification for Damages under <U>Section</U><U></U><U>&nbsp;8.1(b)(ii)</U> to the Purchaser
Indemnified Parties, unless the aggregate amount of all Damages incurred by the Purchaser Indemnified Parties, with respect to breaches of representations or warranties made by Seller in this Agreement or in any Ancillary Agreement (in the
aggregate), exceeds $250,000 (the&nbsp;&#147;<U>Basket</U>&#148;), in which case the obligation to provide indemnification under <U>Section</U><U></U><U>&nbsp;8.1(b)(ii)</U> to the Purchaser Indemnified Parties will apply only with respect to such
amounts as are in excess of the Basket. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exclusive Monetary Remedy</U>. Except for Fraud claims, the indemnification provisions
contained in this <U>Section</U><U></U><U>&nbsp;8.1</U> are intended to provide the sole and exclusive monetary remedy following the Closing as to all Damages any Purchaser Indemnified Party may incur arising from or relating to breaches of any
representation or warranty made by Seller in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Release of Holdback Amount</U>. Promptly following the expiration of
the Survival Period, Purchaser will pay to Seller by wire transfer of immediately available funds to the account designated on <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Disclosure Schedule, the remainder of the Holdback Amount, less any
amounts required to satisfy any then pending claims (&#147;<U>Pending Claims</U>,&#148; and the amounts required to satisfy any such Pending Claims, the &#147;<U>Set Aside Amounts</U>&#148;). Upon the final determination of any such Pending Claims,
Purchaser will be entitled to retain the amount awarded to Purchaser in the final determination of such Pending Claim (the&nbsp;&#147;<U>Indemnified Amount</U>&#148;) with respect to such Pending Claim, if any, and, within five Business Days of the
final determination of such Pending Claim, Purchaser will pay to Seller an amount equal to the excess of (i)&nbsp;the Set Aside Amount with respect to such Pending Claim, <U>minus</U> (ii)&nbsp;the Indemnified Amount with respect to such Pending
Claim to the account designated on <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Disclosure Schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Tax Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) For Tax purposes, the Holdback Amount will be treated as having been received and voluntarily set aside by Seller immediately following
the Closing Date for securing their obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Seller and Purchaser agree to treat (and cause their
Affiliates to treat) any payments received pursuant to this <U>Section</U><U></U><U>&nbsp;8.1</U> as adjustments to the Purchase Price for all Tax purposes, unless otherwise required by a change in Law after the date of this Agreement, a closing
agreement with an applicable Taxing Authority, or a final judgment of a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>Notices</U>.
All notices, requests, demands, and other communications under this Agreement will be in writing and will be deemed to have been duly given or made (a)&nbsp;if sent by registered or certified mail in the United States return receipt requested, upon
receipt, (b)&nbsp;if sent by nationally recognized overnight air courier, one Business Day after mailing, (c)&nbsp;if sent by email, when transmitted and receipt is confirmed by email or telephone, and (d)&nbsp;if otherwise actually personally
delivered, when delivered; in each to the addresses set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">if to Seller, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Catalyst Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">611
Gateway Blvd., Suite 710 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy to (which will not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Orrick, Herrington and Sutcliffe LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">51 West 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10019-6142 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]; [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***]; [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">if to
Purchaser, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vertex Pharmaceuticals Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">50 Northern Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA
02210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Business Development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with copies to (which will not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vertex Pharmaceuticals Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">50 Northern Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA
02210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Corporate Legal </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">500 Boylston Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA
02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]; [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***]; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other
address(es) as will be furnished in writing by any such party to the other party to this Agreement in accordance with the provisions of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3 <U>Expenses</U>. Except as otherwise provided in this Agreement or the applicable Ancillary Agreements, all costs and
expenses (including all fees and disbursements of counsel, financial advisors, and accountants) incurred in connection with the negotiation and preparation of this Agreement and the Ancillary Agreements, the performance of the terms of this
Agreement and the Ancillary Agreements, and the consummation of the Transaction, will be paid by the respective party incurring such costs and expenses, whether or not the Closing will have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>Entire </U><U>Agreement</U>. This Agreement (including the Disclosure Schedule and the Exhibits), the Ancillary
Agreements, and the Confidentiality Agreement constitute the entire agreement of the parties with respect to the subject matter of this Agreement, the Ancillary Agreements, and the Confidentiality Agreement, and supersede all prior agreements and
undertakings, both written and oral, among the parties with respect to the subject matter of this Agreement, the Ancillary Agreements, and the Confidentiality Agreement, except as otherwise expressly provided in any such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5 <U>Severability</U>. In the event that any one or more of the terms or provisions contained in this Agreement or in any other
certificate, instrument, or other document referred to in this Agreement, will, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other term or
provision of this Agreement or any other such certificate, instrument, or other document referred to in this Agreement, and the parties will use their commercially reasonable efforts to substitute one or more valid, legal, and enforceable terms or
provisions into this Agreement which, insofar as practicable, implement the purposes and intent of this Agreement. Any term or provision of this Agreement held invalid or unenforceable only in part, degree, or within certain jurisdictions will
remain in full force and effect to the extent not held invalid or unenforceable to the extent consistent with the intent of the parties as reflected by this Agreement. To the extent permitted by applicable Law, each party waives any term or
provision of Law which renders any term or provision of this Agreement to be invalid, illegal, or unenforceable in any respect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6 <U>Amendments; Waivers</U>. This Agreement may be amended or modified only
by a written instrument executed by both of the parties. Any failure of the parties to comply with any obligation, covenant, agreement, or condition in this Agreement may be waived by the party entitled to the benefits thereof only by a written
instrument signed by the party granting such waiver. No delay on the part of any party in exercising any right, power, or privilege under this Agreement will operate as a waiver thereof, nor will any waiver on the part of any party of any right,
power, or privilege under this Agreement operate as a waiver of any other right, power, or privilege under this Agreement, nor will any single or partial exercise of any right, power, or privilege under this Agreement preclude any other or further
exercise thereof or the exercise of any other right, power, or privilege under this Agreement. Unless otherwise provided, the rights and remedies provided for in this Agreement are cumulative and are not exclusive of any rights or remedies which the
parties may otherwise have at law or in equity. Whenever this Agreement requires or permits consent by or on behalf of a party, such consent will be given in writing in a manner consistent with the requirements for a waiver of compliance as set
forth in this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7 <U>Assignment; Successors and Assigns</U>. Neither this Agreement nor any of the rights,
interests, or obligations under this Agreement will be assigned or transferred by either party (whether by operation of Law or otherwise) without the prior written consent of the other party, and any purported assignment or other transfer without
such consent will be void and unenforceable; <U>provided</U> that Purchaser may assign any of its rights, interests, or obligations under this Agreement to any member of the Purchaser&#146;s Group without the consent of Seller. Subject to the
preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by the parties and their respective successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8 <U>No Third</U><U><FONT STYLE="white-space:nowrap">-Party</FONT> Beneficiaries</U>. This Agreement is for the sole benefit of
the parties and nothing in this Agreement, express or implied, is intended to or will confer upon any other Person (other than a permitted successor or assign of a party) any legal or equitable right, benefit, or remedy of any nature whatsoever
under or by reason of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9 <U>Governing Law; Consent to Jurisdiction</U>. This Agreement and all matters
arising out of or relating to this Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to Contracts executed in and to be performed entirely within such State, without giving effect to the
principles of conflict of Laws that would require or permit the application of the Laws of any other jurisdiction. Each of the parties irrevocably and unconditionally submits, for itself and its assets and properties, to the exclusive jurisdiction
of any court in the Borough of Manhattan, City of New York, State of New York in any Action arising out of or relating to this Agreement, the agreements delivered in connection with this Agreement, or the Transaction, or for recognition or
enforcement of any judgment relating thereto, and each of the parties irrevocably and unconditionally (a)&nbsp;agrees not to commence any such Action except in such courts, (b)&nbsp;agrees that any claim in respect of any such Action may be heard
and determined in such court or, to the extent permitted by Law, in such Federal court, (c)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such
Action in any such court, and (d)&nbsp;waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such Action in any such court. Each of the parties agrees that a final judgment in any such Action will
be conclusive and may be enforced in other jurisdictions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by suit on the judgment or in any other manner provided by Law. Each of the parties irrevocably consents to service of process in the manner provided for notices in
<U>Section</U><U></U><U>&nbsp;8.2</U> and agrees to submit to extraterritorial service of process should such service become necessary. Nothing in this Agreement will affect the right of any party to serve process in any other manner permitted by
applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10 <U>Waiver of Jury Trial</U>. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE
UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTION. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT, OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B)&nbsp;IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C)&nbsp;IT MAKES SUCH WAIVERS VOLUNTARILY, AND
(D)&nbsp;IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11 <U>Specific Performance</U>. The parties agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties will be entitled to specific performance of the terms of this Agreement, including an injunction or injunctions
to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in the courts of the Borough of Manhattan, City of New York, State of New York, this being in addition to any other remedy to which they
are entitled at Law or in equity. Each of the parties further waives (a)&nbsp;any defense in any action for specific performance that a remedy at Law would be adequate, and (b)&nbsp;any requirement under any Law to post security as a prerequisite to
obtaining equitable relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12 <U>Counterparts</U>. This Agreement may be executed in counterparts (including by facsimile
and electronic transmission), each of which when executed will be deemed to be an original, but all of which taken together will constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">CATALYST BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VERTEX PHARMACEUTICALS INCORPORATED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Asset Purchase Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cbio-20220624.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/25/2022 12:48:19 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:cbio="http://www.catalystbiosciences.com/20220624"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.catalystbiosciences.com/20220624"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220624_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220624_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cbio-20220624_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/25/2022 12:48:19 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cbio-20220624_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 6/25/2022 12:48:19 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cbio-20220624.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140624060779488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 24,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CATALYST BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d387575d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbio-20220624.xsd" xlink:type="simple"/>
    <context id="duration_2022-06-24_to_2022-06-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-06-24</startDate>
            <endDate>2022-06-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-06-24_to_2022-06-24">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-06-24_to_2022-06-24"
      id="Hidden_dei_EntityCentralIndexKey">0001124105</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-06-24_to_2022-06-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-06-24_to_2022-06-24">2022-06-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-06-24_to_2022-06-24">CATALYST BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-06-24_to_2022-06-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-06-24_to_2022-06-24">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-06-24_to_2022-06-24">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-06-24_to_2022-06-24">611 Gateway Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-06-24_to_2022-06-24">Suite 710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-06-24_to_2022-06-24">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-06-24_to_2022-06-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-06-24_to_2022-06-24">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-06-24_to_2022-06-24">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-06-24_to_2022-06-24">871-0761</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-06-24_to_2022-06-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-06-24_to_2022-06-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-06-24_to_2022-06-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-06-24_to_2022-06-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-06-24_to_2022-06-24">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-06-24_to_2022-06-24">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-06-24_to_2022-06-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-06-24_to_2022-06-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    (  ^.V%0D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  /CMA499!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ #X[85,8B-.7O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ #X[85)E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  /CMA435Z[H5L$   B$0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ #X[85)^@&_"Q
M @  X@P   T              ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    "  /CMA4EXJ[',     3 @  "P              @ %[#P  7W)E;',O
M+G)E;'-02P$"% ,4    "  /CMA4'#AEZC\!   \ @  #P
M@ %D$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #X[85"0>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ #X[85&60>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d387575d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d387575d8k.htm">d387575d8k.htm</File>
    <File>cbio-20220624.xsd</File>
    <File>cbio-20220624_lab.xml</File>
    <File>cbio-20220624_pre.xml</File>
    <File>d387575dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d387575d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d387575d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20220624_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20220624_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20220624.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cbio",
   "nsuri": "http://www.catalystbiosciences.com/20220624",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d387575d8k.htm",
      "contextRef": "duration_2022-06-24_to_2022-06-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d387575d8k.htm",
      "contextRef": "duration_2022-06-24_to_2022-06-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.catalystbiosciences.com//20220624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-22-181696-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-181696-xbrl.zip
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MOP-W&KN FY7;'_G ;#NNN^UKUT\TVQSI[F8X^NU5NWKHYW=02P,$%     @
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M)ZD?_4V7[>]QZA6>PRCH3>D&82<2;0PTJAT-05X)9"G,^Y;=V6@: &,OEN\
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ME?%L5M3WB'J>_6Z6,EMU>1#02+*._;"80T@10HT,I]G\T:"NTS1@=IHVSD/
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M$6%:SX&&RY"\8WV14&'Y<U_S2#4/;@A$<]$5&E*("=!M\@@+[RC6?ET!JH*
MDM^9'_;!'R-7L)V0";FRY%S]?C7%U57 NI7CNX"#VXFN'8N8VBVA'GA:7$S
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M*Z$!&GN@^TX_GI$M#_[=KI/?TD-4;<:,F4WYOHK.&7 X6!V#%1X"F=^/^K_
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M."/BPV6CY27F<Q%>*J%*_<-(A9AV+$L[92(O[V,>5J)+ %:+01H3<LKK8("
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M:+PGD>.3"8P!+?YVZR"\6N&>[(4C=&XV'M>06#OIXC 3(!_4K=E +,+O8 R
M?H2[$=$S.N0U9><$+C%K;?#GGV5TSDN9I==A@E^A\8P.&#7FSX,T9V-!?9_@
MS@2/XC&VU\9EQ=_((/ ,3SI"<Q,ZYEZ0EL7C=/AXD@Z^J:)C\CX8"@^X..PD
M^65"6/=LK*YS7*27;SOZ[*,GB;_B,_T==UE_,U0J-U^/<_[ /A@P,<7BH25
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MI!X)63J.!SJYZ)IAZ*3O"!R9:WD0^HA8^LJ/ :/E\,,0TCR,$P=<4*,6.Z]
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M1,LO??:81G#N@ZC,-#>OOL&D'HOE>,>I/XH4>^#,5C:\%*$#9"^KF[=E_,!
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M@3*7N[D]%?>."BK+Y3RMKXHKC)0UC;Y#4 U1<)A>D@TE*$ZO.OS'TR=/=YJ
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MY;4V/WUAIFIO$>99X8VK88K<LOV67#%XP$S1Y'W>ABLVP>L^1 ?7RXV#ZQY
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MOD&,QC4@"+I-R%1Z$P>8M'W=;*&.SR:1>PDOI]DLL.X!4$L! A0#%     @
M#X[85 \BXW)+ P  =0L  !$              ( !     &-B:6\M,C R,C V
M,C0N>'-D4$L! A0#%     @ #X[85 MP2LI\!@  NT8  !4
M ( !>@,  &-B:6\M,C R,C V,C1?;&%B+GAM;%!+ 0(4 Q0    (  ^.V%2E
M[FHIR00  %<L   5              "  2D*  !C8FEO+3(P,C(P-C(T7W!R
M92YX;6Q02P$"% ,4    "  /CMA4+FAW/^@5   1@P  #@
M@ $E#P  9#,X-S4W-60X:RYH=&U02P$"% ,4    "  /CMA4*K28J=]W  #(
M0@, $0              @ $Y)0  9#,X-S4W-61E>#DY,2YH=&U02P4&
/  4 !0!  0  1YT

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
